Viewpoints Column Archives
With the first biosimilar approval in March and the FDA’s publishing of biosimilar industry guidance documents in April, it is essential to evaluate different stakeholder perspectives concerning what is already known about biosimilars and what still remains to be determined.
Generic drugs used to be the golden goose for retail pharmacies. But with all of the changes taking place in the generic drug market, the new generic world requires that pharmacy owners remain flexible in their sourcing by examining pricing from several primary and secondary suppliers.
As we begin a new year, we decided that an annual forecast of market changes would be in order. What follows is what we believe will have the greatest impact on pharmacy this year.
The U.S. Department of Health and Human Services Office of Inspector General (OIG) released a report in September questioning pharmaceutical manufacturers’ safeguards to prevent co-pay card use in federally funded programs, specifically Medicare Part D. The OIG voices its concern with the strategies employed by the pharmaceutical manufacturers and their vendors that facilitate the execution of co-pay card programs.
Significant advances have occurred in electronic prescribing over the past few years. A substantial increase in volume was mainly due to the meaningful use of e-prescribing in prescriber systems according to the requirements set by CMS.
Many aspects of pharmacy practice have been shaped by HIPAA and HITECH requirements… Two areas that have recently emerged as potential threats to privacy and security are pharmacy apps and pharmacist-patient interactions outside of the pharmacy counter.
Pharmacy interns may interact with many computer systems within the prescription fulfillment workflow, with the most obvious being the pharmacy computer system. Interns who are educated on the different systems have the ability to impact the profitability of the pharmacy and improve customer service, while providing a head start on having a successful career as a pharmacist.
In the last issue of ComputerTalk we discussed the requirements to be implemented under the the Drug Quality and Security Act (DQSA) in the first three years. Here, we will discuss the longer-term conditions and implementation issues expected from 2017 through 2023, by which time the act will be fully operational.
The key provisions of the Drug Quality and Security Act (DQSA) will be phased in over the next 10 years and will make it easier to trace where a drug has been in the supply chain; detect and remove counterfeit drug products; and facilitate drug recalls when necessary.
We have compiled our annual predictions for what is ahead in 2014, including changes in reimbursement, more critical analysis of technology investments, and the impact of pharmacist supply.
With many Americans looking for healthcare coverage starting Jan. 1, 2014, the importance of understanding the new health insurance exchanges cannot be overstated.
Refill synchronization is emerging as a new, innovative service for retail pharmacy. The service coordinates all of a patient’s maintenance prescriptions to be refilled on the same day each month.
We view this increased online patient contact with healthcare professionals as a huge opportunity for pharmacists to expand their scope of supportive care via telemedicine.
E-prescribing has impacted the way pharmacies conduct their business. However, as technology helps solve problems, it may also create new problems.
Gathering Information for retail pharmacists to be active users, HIEs need to be open to retail pharmacist involvement but pharmacists also share in the responsibility.